

FOR IMMEDIATE RELEASE

Contact: CutisPharma, Inc. Media Relations
media@cutispharma.com

CUTISPHARMA ANNOUNCES NEW MANAGEMENT TEAM APPOINTMENTS

Mike Radice named as Chief Commercial Officer, current Chief Financial Officer Ron Scarboro will also assume role of Chief Operating Officer and Hanok George named as General Counsel

WILMINGTON, Mass. (Jan. 15, 2019) – CutisPharma, Inc. announced today the appointments of Mike Radice as Chief Commercial Officer, Chief Financial Officer Ron Scarboro’s expanded role as Chief Operating Officer, and Hanok George as General Counsel.

“I am pleased to welcome Mike and George to the management team, as well as announce Ron’s expanded role within the organization,” said Neal I. Muni, MD, MSPH, CutisPharma’s Chief Executive Officer. “The depth of expertise and keen insights that Mike, Ron and George bring to my leadership team will be invaluable to the Company as we continue to execute on our goals of pipeline development and bringing new products to market.

Mr. Radice has over 30 years of commercial leadership experience across multiple segments of the pharmaceutical industry, including Vice President of Business Development for Publicis Health Solutions, Vice President and Head of Commercial Operations at IQVIA, VP Sales, Marketing and BD at Antibioticos, Inc., and in his earlier career, positions of increasing leadership responsibility in managed markets as well as sales at Allergan and Searle Pharmaceuticals.

Mr. Scarboro joined CutisPharma as Chief Financial Officer in September 2018 and has over 25 years of executive financial and operational experience in public and private companies ranging from start-up to \$1.5B in annual revenues. Mr. Scarboro’s prior roles include Chief Financial Officer for Clinipace Worldwide, Chief Financial and Information Officer at Comprehensive Pharmacy Services, a leader in pharmacy outsourcing and CFO of M*Modal (NASDAQ: MODL).

Mr. George has served in leadership roles at multinational companies operating in the life sciences, IT, technology, and professional services spaces, and as an attorney at national and international law firms, most recently serving in the Office of General Counsel at Eliassen Group.

In the past year, CutisPharma has announced several significant Company milestones, including the FDA approval and launch of FIRVANQ (vancomycin hydrochloride for oral solution), acquisition by Novaquest Capital Management, LLC in the first quarter of 2018, and more recently, the undertaking of a significant expansion of its manufacturing operations to accommodate its rapidly growing portfolio of products.

About CutisPharma

CutisPharma, Inc., based in Wilmington, MA, is a privately held, specialty pharmaceutical company that has been the industry leader for over 20 years in providing innovative solutions to pharmacists. CutisPharma's FIRST Unit-of-Use Compounding Kits have benefited millions of patients who are unable to swallow conventional oral dosage forms such as tablets and capsules and whose needs are not served by other commercially available therapies. In April 2018, CutisPharma announced the launch of FIRVANQ[®] (vancomycin hydrochloride for oral solution), the only FDA-approved vancomycin oral liquid therapy for patients with *Clostridium difficile*-associated diarrhea. For more information, visit www.cutispharma.com, www.firvanq.com or contact us at media@cutispharma.com.

###